This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

¿Cómo funciona Saxenda®?

Saxenda® es 97% similar al GLP-1 endógeno, trabajando en el cerebro para disminuir el apetito y así reducir la ingesta de alimentos.2,3

Obtenga más información sobre cómo funciona Saxenda®

Una vez al día, Saxenda® inyectable se puede aplicar convenientemente en cualquier momento del día, independiente de las comidas de preferencia a la misma hora todos los días.2

Para ver lo fácil que es para sus pacientes aplicarse Saxenda®

1.- Data on file, Novo Nordisk.

2.- Saxenda®, Información para Prescribir, 16.08.2018 (183300415U0042).

3.- Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665-670.

4.- Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovasculas risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 2011;34(7):1481-1486.

5.- Pi-Sunyer X, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22

6.- Knowler WC, Barrett-Connor E, Fowler SE, et al. for the Diabetes Prevention Program Research Group. Reduction in th e incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med. 2002;346(6):393-403

7.- Tuomilehto H Seppa J, Uusitupa M, et al. The impact of weight reduction in prevention ofb the progression of obstructive sleep apnea: an explanatory analysis of a 5-year observational follow up trial. Sleep Med. 2014;15(3):329-335.

8.- Foster GD Borradaile KE Sanders MH, et al. for the Sleep AHEAD Research Group of the Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD Study. Arch Intern Med. 2009;69(17):1619-1626

9.- Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain and function in persons with symptomatic knee osteoarthritis: a cohort study. Arthritis Care Res. 2013;65(1):15-22

10.- Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins; a meta analysis. Am J Clin Nutr. 1192;56(2)320-328

11.- le Roux CW, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double- blind trial. Lancet. 2017;389(10077):1399-1409.

12.- Wadden TA, Hollander P, Klein S, et al. on behalf of NN8022-1923 Investigators. Weight maintenace and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenanc randomized study. Int J Obes (Lond). 2013; 37(11):1443-1451. [Erratum: Int J Obes (Lond) 2013;37:1514. doi: 10.1038/ijo.2013.148.]